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Systemic blockade of ACVR2B 
ligands prevents chemotherapy-
induced muscle wasting by 
restoring muscle protein synthesis 
without affecting oxidative 
capacity or atrogenes
T. A. Nissinen1, J. Degerman2, M. Räsänen2, A. R. Poikonen1, S. Koskinen3, E. Mervaala4, 
A. Pasternack5, O. Ritvos5,6, R. Kivelä2 & J. J. Hulmi1,6
Doxorubicin is a widely used and effective chemotherapy drug. However, cardiac and skeletal muscle 
toxicity of doxorubicin limits its use. Inhibiting myostatin/activin signalling can prevent muscle 
atrophy, but its effects in chemotherapy-induced muscle wasting are unknown. In the present study 
we investigated the effects of doxorubicin administration alone or combined with activin receptor 
ligand pathway blockade by soluble activin receptor IIB (sACVR2B-Fc). Doxorubicin administration 
decreased body mass, muscle size and bone mineral density/content in mice. However, these effects 
were prevented by sACVR2B-Fc administration. Unlike in many other wasting situations, doxorubicin 
induced muscle atrophy without markedly increasing typical atrogenes or protein degradation 
pathways. Instead, doxorubicin decreased muscle protein synthesis which was completely restored by 
sACVR2B-Fc. Doxorubicin administration also resulted in impaired running performance without effects 
on skeletal muscle mitochondrial capacity/function or capillary density. Running performance and 
mitochondrial function were unaltered by sACVR2B-Fc administration. Tumour experiment using Lewis 
lung carcinoma cells demonstrated that sACVR2B-Fc decreased the cachectic effects of chemotherapy 
without affecting tumour growth. These results demonstrate that blocking ACVR2B signalling may be 
a promising strategy to counteract chemotherapy-induced muscle wasting without damage to skeletal 
muscle oxidative capacity or cancer treatment.
Cancer-related cachexia has been suggested to account for up to 20–30% of all cancer deaths1. In addition, 
decreased skeletal muscle mass is associated with increased toxicity of chemotherapy and impaired prognosis2. In 
contrast, maintenance of skeletal muscle mass predicts better response to treatment and survival2,3. Therefore, it 
is crucial to discover and develop effective strategies to counteract chemotherapy-induced muscle loss.
Doxorubicin is a widely used and effective anthracycline chemotherapeutic agent. Some of its most important 
antineoplastic effects are suggested to include prevention of DNA replication via DNA Topoisomerase II inhi-
bition, DNA damage via formation of reactive oxygen species (ROS) and apoptosis (programmed cell death)4. 
However, doxorubicin has deleterious effects on several tissues other than tumour, which limits its clinical use. 
Particularly well-known side-effect is doxorubicin-induced cardiotoxicity4,5. Doxorubicin has also been shown 
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to have adverse effects on skeletal muscle tissue: muscle weakness, fatigue, dysfunction and atrophy have been 
reported in both humans4,6 and animals4,7–11 after chemotherapy. The proposed cellular and molecular mech-
anisms for skeletal muscle toxicity, at least with high doses, include oxidative stress induced by doxorubicin 
accumulating into skeletal muscle, which may lead to contractile and mitochondrial dysfunction associated with 
activation of proteolytic and apoptotic signalling pathways4,8,9,12. Protein degradation pathways have been exten-
sively studied in different muscle atrophy models and in human diseases13. In adults, muscle size is, however, 
regulated by the balance between protein synthesis and degradation14. Currently, the effect of doxorubicin on 
muscle protein synthesis is unknown.
Muscle size is negatively regulated by myostatin and activins that belong to the TGF-β superfamily of pro-
teins15,16. They exert their effect through binding to their receptor activin receptor type IIb (ACVR2B)17. An 
often used strategy to prevent muscle loss in animal models is to block these ACVRIIB ligands by administra-
tion of a soluble ligand binding domain of ACVR2B fused to the Fc region of IgG (sACVR2B-Fc). This strategy 
has been shown to increase muscle mass effectively in mice17–19. In addition, sACVR2B-Fc treatment has been 
found to reverse cancer cachexia and prolong survival in different mouse models of cancer cachexia20,21. However, 
blocking ACVR2B ligands can also, depending on the context, have adverse effects22–24. It is not known whether 
sACVR2B-Fc administration could prevent doxorubicin-induced muscle atrophy without negatively altering 
muscle oxidative capacity.
The effects of blocking ACVR2B signalling on muscle growth in healthy mice have been shown earlier by 
us and others19,25. In the present study we investigated the effects of systemic doxorubicin administration alone 
or combined with sACVR2B-Fc treatment on skeletal muscle size and function and the underlying molecular 
mechanisms. For this purpose, five doxorubicin experiments were performed: 1–2) two four-week experiments, 
3) a two-week experiment, 4) an acute 20 h experiment, and 5) a tumour experiment with doxorubicin treatment. 
The dose of doxorubicin was selected to mimic clinical doses used in humans. These studies demonstrate that 
doxorubicin induces muscle atrophy that is, at least in part, due to blunted skeletal muscle protein synthesis. We 
also showed that blocking ACVR2B signalling can counteract chemotherapy-induced muscle loss without further 
damage to skeletal muscle oxidative capacity or mitochondria. Importantly, sACVR2B-Fc administration did not 
affect tumour growth or the effect of doxorubicin on tumour growth.
Results
sACVR2B treatment prevents doxorubicin-induced skeletal muscle atrophy but not loss of fat. 
In the first experiments, mice were given a total cumulative dose of 24 mg/kg of doxorubicin (comparable to clin-
ical dose5,26), or PBS, during the first two weeks of the experiment. In the four-week experiment, doxorubicin was 
not administered during the latter two weeks and thus the results represent more chronic effects of doxorubicin 
treatment. This doxorubicin administration resulted in marked decrease in body weight (Fig. 1a). The weight loss 
was most dramatic during the second week of doxorubicin administration and the reduced body weight was sus-
tained after the cessation of doxorubicin administration (Fig. 1a). This was accompanied by a significant reduc-
tion in tissue masses of tibialis anterior (TA) and gastrocnemius muscles and epididymal fat pads determined 
upon euthanasia (Fig. 1b–e and Supplementary Fig. S1a–d). These findings were substantiated by dual-energy 
X-ray absorptiometry (DXA) analysis, which showed a significant decrease in lean mass and fat mass (Fig. 1f,g). 
sACVR2B-Fc treatment fully prevented the doxorubicin-induced decrease in body mass, lean mass and skel-
etal muscle weights and could even induce hypertrophy when compared to untreated healthy mice. However, 
sACVR2B-Fc treatment was unable to prevent the decrease in fat mass, which was even slightly exacerbated. 
Doxorubicin treated mice ate significantly less compared with the vehicle treated counterparts. sACVR2B-Fc 
treatment did not have any additional effect on feed consumption (Fig. 1h).
In line with skeletal muscle weights, doxorubicin treated mice tended (P = 0.075) to have decreased average 
muscle fibre cross-sectional area (CSA) in TA muscle (Fig. 2a,c) and fibre frequency curve shifted towards smaller 
fibres (Fig. 2b). This decrement was completely prevented by sACVR2B-Fc administration which resulted in sig-
nificantly increased fibre size compared with both controls and doxorubicin treated mice (Fig. 2a–c).
Blocking of the muscle loss prevents decrease in bone quality. To further investigate the potential 
positive effects of maintaining muscle mass during chemotherapy, bones were analysed as a downstream out-
come of the treatments. DXA-analysis showed a decrement in bone mineral density (BMD) and in bone mineral 
content (BMC) in doxorubicin-treated mice when compared to controls, whereas sACVR2B-Fc prevented these 
adverse effects (Fig. 3a,b). Our association analysis using a computationally determined network27 showed that 
BMD and BMC at the end and the change in BMD and BMC are highly correlated to changes in lean mass as well 
as the end-measures of muscle mass and muscle fibre CSA (Fig. 3c–f).
Doxorubicin administration resulted in chronic impairment of treadmill running capacity. 
Doxorubicin treated mice had significantly impaired maximal running performance in an incremental treadmill 
running test (Fig. 4). sACVR2B-Fc treatment did not have any effect on running performance.
Doxorubicin induces muscle atrophy with only small alterations in proteolytic path-
ways. To investigate the factors that might contribute to doxorubicin-induced muscle atrophy and its 
reversal by sACVR2B-Fc, an acute experiment was conducted. Non-tumour bearing mice received a single 
intraperitoneal injection of doxorubicin (15 mg/kg in PBS) and were euthanized 20 hours post injection. Half 
of the doxorubicin treated mice were administered with sACVR2B-Fc (10 mg/kg in PBS) 48 hours before 
doxorubicin administration, as it has previously been reported that sACVR2B-Fc increases muscle protein 
synthesis 48 hours after its administration19. Microarray analysis was conducted from TA muscle to study 
gene expression responses to the treatments. To find out whether doxorubicin-induced muscle atrophy was 
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Figure 1. Doxorubicin administration resulted in decreased body and muscle weights that were restored 
by sACVR2B-Fc treatment. (a) Body weights during the four-week experiment. Arrows indicate the timing of 
doxorubicin (orange) and sACVR2B-Fc (blue) injections. Repeated measures ANOVA revealed time x group 
interaction effect (P < 0.001). Tissue weights of TA (b), gastrocnemius (GA) (c) and soleus (d) muscles and 
epididymal fat pads (e) relative to tibial length (Supplementary Fig. S1e). Percentage changes in lean (f) and fat 
(g) mass analysed with DXA. (h) Average feed consumption during and after the treatment with doxorubicin 
and sACVR2B-Fc. Average feed consumption per mouse was calculated from the pooled feed intake of the 
whole cage (2–3 mice/cage; N = 3–4 cages/group). N sizes are depicted in the bar graphs. Data are presented 
as mean ± SEM. In Fig. a: #P < 0.05 compared to Ctrl; **P < 0.01 compared to Ctrl and Dox + sACVR2B 
(Bonferroni). In Figs. b–h: *P < 0.05; **P < 0.01; ***P < 0.001 (Bonferroni).
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due to increased protein catabolism, a common atrogene signature for genes that has previously been shown 
to be commonly down- or upregulated in fasting, cancer cachexia, renal failure, diabetes, and in loss of con-
tractile activity28 was investigated (listed in Table 1). There were no systematic changes by doxorubicin or 
by sACVR2B-Fc on these transcripts (Table 1). There was however a minor trend that the atrogenes tended 
to follow the same trend in doxorubicin-administered mice as earlier28, although with a much smaller mag-
nitude than with the other muscle wasting situations. Therefore, a gene set enrichment analysis (GSEA), able 
to detect small changes in several genes29, was conducted. Indeed, a custom-made gene set for these atrogenes 
showed a small increased enrichment (normalized enrichment score (NES) 1.44, FDR = 0.05) in doxorubicin 
administered mice when compared to vehicle treated control mice (Supplementary Fig. S2a) and this was 
blocked by sACVR2B-Fc administration (Supplementary Fig. S2b). GSEA analysis also revealed a small, but 
significant increase due to doxorubicin in the proteasome pathway (FDR = 0.041, Supplementary Fig. S2c,d) 
and also a trend in the caspase cascade (NES 1.75, FDR = 0.051) without any effect of sACVR2B-Fc. Of the 
individual atrogenes, FOXO1 was the only one that was significantly (adjusted P < 0.05) induced by doxorubicin 
(Table 1, Supplementary Fig. S2a). Thus, FoxO1 protein level and its phosphorylation were analysed. Similarly 
as in the microarray analysis, total FoxO1 protein expression was increased significantly (P < 0.05) by doxoru-
bicin, whereas phosphorylated FoxO1 remained at similar level between the groups (Supplementary Fig. S3a,e). 
In addition, mRNA expression of a well-known atrogene, MuRF1, was confirmed with qPCR, which, in accord-
ance with the microarray result, showed no effect of doxorubicin treatment (Supplementary Fig. S3b). However, 
sACVR2B-Fc decreased MuRF1 mRNA (Supplementary Fig. S3b).
To study protein degradation pathways further, common markers of ubiquitin-proteasome system, auto-
phagy and calpain content were analysed by western blotting. Doxorubicin administration did not result in any 
acute or chronic alterations in ubiquitinated proteins, lipidated LC3, or calpain1 protein content (Fig. 5a–d). 
No changes were noticed acutely or at 4 weeks, but at two weeks, sACVR2B-Fc treatment resulted in decreased 
lipidated LC3 (Fig. 5b). As LC3 lipidation alone is not sufficient marker for autophagy30, we also checked gene 
expression changes related to autophagy. Supporting the results above, autophagy gene set (KEGG) was not 
regulated by doxorubicin (FDR = 0.48, Supplementary Fig. S4a). Also after adjustment, the only significantly 
increased genes in this pathway were slightly increased Ulk1 (1.41 fold, P = 0.02) and Becn1 (1.31 fold, P = 0.01) 
in doxorubicin-administered mice, without marked effects of sACVR2B-Fc (Supplementary Fig. S4a,b). 
Doxorubicin has previously been shown to increase apoptosis, also in skeletal muscle31. Indeed, GSEA analysis 
revealed small increase in the gene set of apoptosis (NES 1.9, FDR = 0.01) without any effect of sACVR2B-Fc 
(Supplementary Fig. S4c,d).
To examine the possible delayed effects on muscle regeneration, TA muscles from mice from the four-week 
experiment were analysed for centrally nucleated fibres. Doxorubicin administration did not result in markedly 
and consistently increased number of centrally nucleated fibres (data not shown).
Figure 2. sACVR2B-Fc administration increased muscle fibre cross-sectional area in doxorubicin-treated 
mice. Average fibre CSA (a) and fibre size distribution (b) of the TA muscle at the end of the four-week 
experiment. (c) Representative immunofluorescence images of dystrophin-stained muscle cryosections. Data 
are presented as mean ± SEM. **P < 0.01; ***P < 0.001 (Bonferroni).
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Doxorubicin administration results in blunted skeletal muscle protein synthesis which is 
restored by sACVR2B-Fc treatment. As only small effects were seen in the expression of negative regu-
lators of muscle size, the effects of doxorubicin and sACVR2B-Fc administration on positive regulators of mus-
cle mass and protein synthesis were investigated. To study protein synthesis, a previously published method of 
surface sensing of translation (SUnSET)32,33 was applied as earlier in our laboratory19. This analysis revealed that 
muscle protein synthesis was significantly blunted 20 hours after doxorubicin administration compared with the 
controls (Fig. 6a,b). This decrease in protein synthesis was completely inhibited in mice treated with sACVR2B-Fc 
48 hours prior to the exposure to doxorubicin (Fig. 6a,b). This was accompanied by increased mTORC1 sig-
nalling illustrated by elevated phosphorylation of its downstream targets rpS6 and p70S6K1 in sACVR2B-Fc 
treated mice acutely, but less so in the later time-points (Fig. 6c,d,g). However, at all the time-points investigated, 
no change in the activation of mTORC1 signalling was observed by doxorubicin, which suggests that doxoru-
bicin and sACVR2B-Fc are affecting different pathways regulating muscle mass. Additionally, no changes due 
to the treatments were observed in the phosphorylation of Akt (at Ser473) or the phosphorylation of 4EBP1 (at 
Thr37/46) (Supplementary Fig. S3c–e).
Increased phosphorylation of eIF2α on Ser51 inhibits translation initiation and it has been associated with 
decreased muscle protein synthesis34 and cachexia14. However, the western immunoblot analysis did not show 
any significant doxorubicin-induced changes in eIF2α phosphorylation (Fig. 6e,g). Interestingly, sACVR2B-Fc 
decreased the phosphorylation of eIF2α compared to control (Fig. 6e,g). Another pathway regulating muscle 
size, partially parallel to mTORC1 signalling, is MAPK signalling. The phosphorylation of ERK 1/2 was acutely 
downregulated in doxorubicin treated mice, while sACVR2B-Fc treatment prevented this decrease (Fig. 6f,g). At 
Figure 3. sACVR2B-Fc treatment improved bone quality in doxorubicin treated mice. Changes in bone 
mineral density (a) and content (b) in the four-week experiment. (c) Associations between muscle and lean 
mass and bone parameters. (d) Associations between muscle size, fat mass and BMD. Correlations between 
change in lean mass and change in BMD (e, r = 0.70, P < 0.001) and BMC (f, r = 0.72, P < 0.001). Data are 
presented as mean ± SEM. **P < 0.01; ***P < 0.001 (Bonferroni).
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two and four weeks, the phosphorylation level of ERK 1/2 was similar between doxorubicin only treated mice 
and control mice.
REDD1 is highly upregulated in doxorubicin-induced muscle loss. To unravel the factors potentially 
underlying doxorubicin-induced decrease in protein synthesis and muscle size, microarray data was analysed for 
genes most induced by doxorubicin known to regulate muscle protein synthesis and size. Doxorubicin treated 
mice showed a significant 2-fold (adjusted P = 0.02) increase in mRNA expression of REDD1, a protein previ-
ously connected to muscle wasting14,35. This increase was confirmed by qPCR, which showed a 3-fold increase in 
REDD1 expression in doxorubicin treated mice (Fig. 6h). The effect of doxorubicin on REDD1 expression was 
partially blocked by sACVR2B-Fc treatment.
Skeletal muscle mitochondrial function and content are not chronically altered in response 
to doxorubicin administration. To explore potential factors explaining impaired running capacity of the 
doxorubicin treated mice, skeletal muscle mitochondrial function was analysed with OROBOROS Oxygraph-2k 
high-resolution respirometer. At the four-week time-point, two weeks after cessation of doxorubicin administra-
tion, the analysis showed no differences in mitochondrial respiratory function of TA muscle between the three 
groups (Fig. 7a). This occurred independent of whether the results were presented as oxygen flux per wet weight 
of tissue or normalized to total TA weight or to an index of mitochondrial content. To study skeletal muscle mito-
chondrial function and content further, citrate synthase activity and expression of several mitochondrial proteins 
were analysed. Doxorubicin did not seem to alter citrate synthase activity, while increased activity was seen in 
mice treated with sACVR2B-Fc (Fig. 7b). Similarly as mitochondrial function, the total content of mitochondrial 
respiratory chain subunits (total OXPHOS) and cytochrome c (cyt c) protein remained unchanged in TA muscle 
irrespective of the treatment (Fig. 7c–e). However, an ion channel protein between cytosol and mitochondrial 
matrix, porin/VDAC136, was significantly elevated in sACVR2B-Fc treated mice (Supplementary Fig. S5a,h). 
Of individual OXPHOS proteins, mitochondrial respiratory chain CI-NDUFB8 and CV-ATP5A were decreased 
in sACVR2B-Fc treated mice compared with doxorubicin only treated mice (Supplementary Fig. S5b–f). 
No differences were detected in the PGC-1α protein (Supplementary Fig. S5g,h) or different PGC-1α isoforms by 
either doxorubicin alone or combined with sACVR2B-Fc (Supplementary Fig. S6a–d).
Skeletal muscle oxygen carrying capacity, but not capillary density, is altered in response to 
doxorubicin administration. To study if blood oxygen carrying capacity was altered due to the treatments, 
haematological parameters were investigated at two and four weeks. Doxorubicin administration independently 
of sACVR2B-Fc administration resulted in decline in blood haemoglobin and haematocrit at two weeks (imme-
diately after treatment), but this effect disappeared at four weeks (Supplementary Fig. S7a–d).
As no major differences were found in skeletal muscle mitochondrial function or content, capillary 
count was analysed from TA. There were no significant effects of doxorubicin or sACVR2B-Fc treatment on 
capillary-to-fibre ratio or capillary density (Fig. 8a–c).
sACVR2B administration did not have any effect on tumour growth or on the antineoplastic 
effect of doxorubicin. To investigate whether the sACVR2B-Fc treatment has effect on the antineoplastic 
effect of chemotherapy or tumour growth, a two-week tumour experiment using the Lewis lung carcinoma (LLC) 
model was conducted. LLC-cancer did not induce muscle atrophy yet at this time-point (Supplementary Fig. S8a–d). 
Similarly as with doxorubicin treated non-tumour bearing mice, doxorubicin treatment seemed to be associated 
with increased loss of lean and fat mass also in tumour bearing mice (Supplementary Fig. S8c–e,g,h) despite 
relatively low cumulative dose (12 mg/kg) of doxorubicin used. sACVR2B-Fc increased skeletal muscle and lean 
Figure 4. Doxorubicin-treated mice had significantly impaired running capacity with no effect of 
sACVR2B-Fc. Distance covered in an incremental treadmill running test until exhaustion. Data are presented 
as mean ± SEM. *P < 0.05; **P < 0.01 (Bonferroni).
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Accession no. Gene
Dox vs. Ctrl Dox + sACVR2B vs. Dox
FC P adj. FC P adj.
Protein degradation
 NM_001039048.2 MuRF1 1.01 0.979 0.72 0.322
 NM_026346.1 Fbxo32 1.81 0.200 0.46 0.196
 NM_009984.2 Ctsl 0.99 0.976 0.97 0.931
 NM_011971.4 Psmb3 1.04 0.564 1.03 0.841
 NM_026545.2 Psmd8 0.89 0.134 1.27 0.041*
 NM_178616.2 Psmd11 1.02 0.859 0.95 0.882
 NM_008945.2 Psmb4 1.07 0.439 0.97 0.884
 XM_001479832.1 UBC 1.07 0.469 0.95 0.848
 NM_021522.2 Usp14 1.06 0.797 1.09 0.898
 NM_134013.3 Psme4 1.12 0.434 0.87 0.367
 NM_011664.3 Ubb 1.14 0.133 0.96 0.737
 XM_284425.1 Uba52 1.00 0.986 1.02 0.955
 NM_011965.2 Psma1 1.02 0.911 1.00 0.989
 NM_001033865.1 Rps27a 1.02 0.924 1.09 0.805
Glycolysis
 NM_145614.3 DLAT 0.99 0.966 1.04 0.914
 NM_010699.1 Ldha 1.03 0.789 1.04 0.783
 NM_011079.2 Phkg1 0.93 0.561 0.94 0.881
 NM_009415.1 Tpi1 0.93 0.613 1.09 0.724
 NM_023418.2 Pgam1 0.98 0.877 1.02 0.959
 NM_018870.2 Pgam2 0.87 0.297 1.03 0.942
ATP synthesis
 NM_007505.2 Atp5a1 1.02 0.953 1.00 1.000
 NM_198415.2 Ckmt2 1.10 0.404 0.95 0.805
 NM_028388.1 Ndufv2 0.99 0.960 0.98 0.967
 NM_026255.4 Slc25a6/Slc25a26 1.00 1.000 0.95 0.800
 NM_145518.1 Ndufs1 0.99 0.955 1.04 0.817
 NM_008618.2 Mdh1 1.01 0.970 0.94 0.825
Other
 NM_011830 IMPDH2 0.99 0.983 1.03 0.968
 NM_024188.5 Oxct1 1.17 0.163 0.81 0.043*
Transcription
 NM_009372.2 Tgif1 1.22 0.285 0.69 0.151
 NM_019739 Foxo1 1.73 0.021* 0.76 0.567
 XM_001478948.1 Ezh1 1.06 0.585 0.96 0.884
 NM_009716.2 Atf4 1.00 0.995 0.95 0.931
 NM_008416.1 Junb 0.98 0.979 1.08 0.941
Translation
 XR_033381.1 Sat 1.11 0.518 0.95 0.903
 NM_007918.3 Eif4ebp1 1.14 0.601 1.11 0.844
 NM_013506 Eif4a2 0.98 0.908 1.01 0.984
 AK019693 Eif4g3 1.00 0.987 0.96 0.850
 NM_027204.2 Mrpl12 0.87 0.171 1.16 0.125
Extracellular matrix
 NM_008495.1 Lgals1 0.95 0.888 1.06 0.924
 NM_015784.2 OSF-2/Postn 1.01 0.953 0.97 0.868
 NM_007742.2 Col1a1 0.85 0.401 0.76 0.792
 NM_007737.2 Col5a2 0.98 0.795 1.03 0.884
 NM_007993 Fbn1 0.79 0.491 1.05 0.964
 NM_010233.1 Fn1 0.96 0.872 0.82 0.326
Miscellaneous
 NM_013602.2 Mt1 1.11 0.774 1.15 0.696
 NM_019930.1 RANBP9 1.19 0.213 0.95 0.857
 NM_009974.2 Csnk2a2 0.91 0.461 1.03 0.940
Continued
www.nature.com/scientificreports/
8Scientific RepoRts | 6:32695 | DOI: 10.1038/srep32695
mass similarly in tumour bearing mice irrespective of doxorubicin administration (Supplementary Fig. S8c,d,g). 
Interestingly, in contrast to the results from doxorubicin experiments in non-tumour bearing mice, in this setting, 
sACVR2B-Fc treatment also protected from the excessive loss of epididymal fat by doxorubicin, but not from the 
loss of total fat mass (DXA) (Supplementary Fig. S8e,h). The tumours of the sACVR2B-Fc treated mice had sim-
ilar response to doxorubicin treatment compared to mice not treated with sACVR2B (Supplementary Fig. S8f). 
These results suggest that inhibiting ACVR2B ligands can decrease the cachectic effects of chemotherapy without 
adversely affecting tumour growth or compromising the antineoplastic effect of chemotherapy on the tumour.
Discussion
Cancer-therapy aiming to treat malignancies can be associated with toxicities in various tissues, such as skel-
etal muscle, and also with shorter life span2,3. In the present study we show that prevention of doxorubicin 
chemotherapy-induced muscle atrophy can be achieved by preventing decreased muscle protein synthesis using 
a blocker for ACVR2B ligands without negative side-effects on aerobic capacity or tumour growth.
Doxorubicin administration resulted in marked decrease in body weight, comprised of loss of both lean and 
fat mass. Skeletal muscle atrophy was observed as a decrease in muscle masses and in TA fibre size. These results 
Accession no. Gene
Dox vs. Ctrl Dox + sACVR2B vs. Dox
FC P adj. FC P adj.
 NM_016792 TXNL 1.01 0.969 1.00 0.993
 NM_013494.2 CPE 1.02 0.937 0.90 0.449
 NM_013645.3 Pvalb 0.87 0.208 1.02 0.948
 NM_008409.2 Itm2a 0.92 0.736 1.26 0.192
 NM_053078.3 Nrep/P311 0.88 0.672 0.73 0.199
Table 1.  Atrogenes previously altered by systemic diseases in mice (fasting, tumor, uremia, diabetes 
mellitus) as well as disuse28. No common changes in muscle were observed due to doxorubicin or 
sACVR2B-Fc on atrogenes involved in protein degradation, energy production, growth transcription/
translation, genes coding extracellular matrix proteins or other genes. FC = fold change and P adj. = adjusted 
p-value using the Benjamini and Hochberg (false discovery rate, FDR) method. *P < 0.05.
Figure 5. Doxorubicin administration did not cause marked alterations in the markers of ubituitin-
proteasome system, autophagy or calpain1 content. Time-course of protein ubiquitination (a) and LC3-I and 
-II content (N = 5–9/group) (b) relative to Ctrl and calpain1 content at 20 h relative to Dox (c) in TA muscles. 
(d) Representative blots of LC3 and calpain1. Data are presented as mean ± SEM. *P < 0.05 (Mann-Whitney U). 
C = Ctrl; D = Dox; D+ A = Dox+ sACVR2B.
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Figure 6. Doxorubicin administration resulted in decreased muscle protein synthesis that was restored by 
sACVR2B-Fc. (a) Muscle protein synthesis relative to Dox analysed with puromycin incorporation method and 
(b) representative blot (left) with Ponceau S staining (right). (− = negative control for puromycin). (c) Time-
course of rpS6 phosphorylation at Ser240/244 relative to Ctrl in TA muscle. p70S6K (Thr389) (d) and eIF2α 
(Ser51) (e) phosphorylation response 20 hours after a single dose of doxorubicin relative to Dox. (f) Time-
course of ERK 1/2 phosphorylation at Thr202/Tyr204 relative to Dox in TA muscle. (g) Representative blots of 
rpS6, p70S6K, eIF2α and ERK 1/2. (h) REDD1 mRNA expression normalized to 36b4 expression relative to 
Ctrl in TA muscle 20 hours after a single dose of doxorubicin. Data are presented as mean ± SEM. *P < 0.05; 
**P < 0.01; ***P < 0.001 (Bonferroni (a;h), Mann-Whitney U -test (c–f)).
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are consistent with previous studies10,11,37. The reduced fat mass and muscle size by doxorubicin might be at least 
partially explained by reduced feed intake. However, as doxorubicin has been shown to accumulate in skeletal 
muscle tissue38, it is possible that doxorubicin also had a direct effect on skeletal muscle. Indeed, doxorubicin 
accumulation was detected in skeletal muscles, and it acutely led to a typical p53 and DNA-damage response 
(unpublished observations) in line with previous reports in cardiac muscle5,39. Importantly, treatment of muscle 
atrophy by blocking ACVR2B ligands was accomplished without any adverse effects on tumour, as shown earlier 
with several other tumour models20,21, or on the effect of doxorubicin on tumour.
Muscle atrophy is a result of a situation in which the rate of protein synthesis is, over a period of time, 
repressed relative to that of degradation. Protein synthesis responses in muscle atrophy have been overall less 
investigated than protein degradation pathways13,14. The present results show, for the first time, that doxorubicin 
administration acutely results in blunted protein synthesis in skeletal muscle. Previous studies have reported 
either repressed40 or unchanged41 protein synthesis in cardiac muscle or cardiomyocytes after acute doxorubicin 
administration. Importantly, the decreased muscle protein synthesis by doxorubicin was completely prevented by 
Figure 7. Doxorubicin administration did not affect mitochondrial function or markers of mitochondrial 
content in skeletal muscle. (a) Mitochondrial respiration in homogenized TA muscle with carbohydrate 
substrates (N = 7–8/group). Cyt c = cytochrome c; CI/II = complex I/II; ETS = electron transfer system.  
(b) Citrate synthase (CS) activity measured from TA muscle. Quantification of total content of mitochondrial 
respiratory chain subunits (c) and cytochrome c (Cyt c) relative to Dox (d) and representative blots (e). Data are 
presented as mean ± SEM. **P < 0.01 (Bonferroni (a–b), Mann-Whitney U (c–d)).
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sACVR2B-Fc administration. The increased protein synthesis by sACVR2B-Fc is likely due to increased mTORC1 
signalling manifested by increased phosphorylation of p70S6K and rpS6. These markers of mTORC1 signalling 
also positively correlated with protein synthesis (Supplementary Fig. S9a). This is consistent with previous results 
from our laboratory, which showed that sACVR2B-Fc treatment in healthy wildtype mice increased muscle size, 
protein synthesis and mTORC1 signalling19. However, doxorubicin did not seem to affect this pathway at least 
at 20 h time-point as phosphorylation levels of p70S6K and rpS6 were similar to control group. This does not 
exclude the possibility that decrease in mTORC1 signalling would have preceded the decreased protein synthesis.
In the present study, no major changes were observed in protein degradation markers such as ubiquitinated 
proteins, atrogene expression28, or markers of autophagy. However, the slight enrichment of the atrogene, protea-
some and apoptosis gene sets in response to doxorubicin administration might indicate at least a small increase 
in protein degradation and apoptosis. The previous available evidence on protein degradation and apoptosis 
pathways suggests activated calpain-caspase-3-apoptosis pathway9,11,42, and increased markers of ubiquitin–pro-
teasome system9, and autophagy43 as contributors to doxorubicin-induced muscle atrophy, but the evidence is 
inconsistent31,44. The reason why we observed only very small upregulation in the protein degradation and apop-
tosis pathways can be speculated to be the dosage of doxorubicin used in our study, i.e. 24 mg/kg cumulative 
dose or 15 mg/kg single dose in the acute experiment. The 15–24 mg/kg in mice is equivalent to ~45–72 mg/m2 
in humans and thus very close to the clinical doses used in cancers (30–90 mg/m2)5. These doses are relatively 
small compared to the ones typically used in the rat studies, i.e. 20 mg/kg in rats11,37,42 that can be estimated to be 
equivalent to ~40 mg/kg in mice and ~120 mg/m2 in humans26. Nevertheless, although the mechanisms behind 
doxorubicin-induced muscle atrophy can be dose-dependent9, the blockade of decreased protein synthesis with-
out major alterations in the protein degradation, apoptosis or autophagy pathways seems to be the mechanism 
by which sACVR2B-Fc prevents doxorubicin-induced muscle loss. However, part of the increased protein syn-
thesis may also be due to larger de novo protein synthesis, as we have shown earlier that sACVR2B-Fc increases 
muscle protein synthesis also in healthy mice19. Moreover, a decrease in the ubiquitin ligase MuRF1 mRNA by 
sACVR2B-Fc was noticed supporting previous studies by Rahimov et al. in wildtype mice and Zhou et al. in 
cachectic mice20,25. This shows a potential for sACVR2B-Fc in preventing atrophy also in situations where protein 
degradation pathways are more strongly activated.
A transcriptome analysis was conducted to investigate if genes previously shown to have a role in mus-
cle atrophy were regulated by doxorubicin. Interestingly, REDD1, a DNA damage marker protein that has 
previously been connected to muscle wasting and decreased protein synthesis14 also in other models, e.g. 
Figure 8. Doxorubicin administration did not affect skeletal muscle capillary density. Quantification of the 
capillary-to-fibre ratio (a) and the number of capillaries per muscle area (b) in TA muscle. (c) Representative 
immunofluorescence images of CD31/PECAM-1 staining for capillaries. Notice that the representative 
capillary images are from exactly the same location as the dystrophin staining in Fig. 2c. Data are presented as 
mean ± SEM. *P < 0.05 (Bonferroni).
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streptozotocin-induced experimental type 1 diabetes35, was one of the most highly upregulated genes. A nega-
tive correlation between REDD1 expression and protein synthesis was observed (Supplementary Fig. S9b). This 
suggests that doxorubicin-induced REDD1 expression could, in part, contribute to decreased protein synthe-
sis, but more mechanistic evidence is needed to verify this connection. Another candidate associated with the 
regulation of muscle size is MAPK-signalling45,46. Doxorubicin administration resulted in marked decrease in 
ERK 1/2 phosphorylation. Similar decrease in ERK phosphorylation has been previously reported five days after 
doxorubicin dose identical to our acute experiment (15 mg/kg) in mouse skeletal muscle31. The physiological 
importance of altered ERK 1/2 MAPK-signalling is unknown, and may be dependent on time-point and con-
text19,45–47. Interestingly, in our setting, sACVR2B-Fc administration restored ERK 1/2 phosphorylation to the 
level of control mice. We have shown earlier that sACVR2B-Fc treatment decreased the phosphorylation of ERK 
1/2 at early, but not at later time-points in healthy mice19. This shows that, in addition to the many other pathways, 
such as mTORC1 signalling, the regulation of MAPK signalling by blocking ACVR2B receptor ligands can also 
be dependent on timing and context. More research is needed to determine the consequences and importance 
of the doxorubicin-induced decrease in ERK 1/2 phosphorylation and prevention of this response by blocking 
sACVR2B ligands.
Several studies have investigated the effects of exercise training on the effects of doxorubicin. Majority42,43,48, 
but not all49 of these studies suggest that exercise training protects against the adverse effects of doxorubicin on 
cardiac and skeletal muscle without compromising50 or even enhancing its antitumor efficacy49. On the other 
hand, maximal aerobic capacity on a whole-body level has been associated with longevity and health51. Muscle 
weakness and fatigue as well as skeletal muscle contractile dysfunction have been reported after exposure to 
doxorubicin in patients4 and in animal models ex vivo4,8,12. However, to the knowledge of the authors, the present 
study is the first one to show direct negative effects of doxorubicin administration on maximal aerobic running 
capacity in vivo. As this effect was observed two weeks after the cessation of doxorubicin administration, it seems 
that the impairment in aerobic capacity is sustained.
Impaired running performance by doxorubicin could have been expected to be accompanied by decreased 
mitochondrial respiratory capacity, but this was not the case in the present study. According to the previous 
literature, doxorubicin can cause impaired mitochondrial function in cardiac52,53 and in skeletal muscle10,37,53. 
However, the evidence concerning skeletal muscle is inconsistent: not all studies report significant impairments 
in the markers of mitochondrial function in response to doxorubicin treatment52. In addition, Gouspillou and 
colleagues10 did not observe any significant or sustained impairment in skeletal muscle mitochondrial respiratory 
function after two cycles of doxorubicin treatment (cumulative dose 20 mg/kg) in mice. However, four cycles of 
treatment (cumulative dose 40 mg/kg) resulted in impaired mitochondrial respiration that was sustained over a 
12-week period after the last cycle10. In that study mice were also treated with dexamethasone, so the contribution 
of each drug to the effects cannot be confirmed10. Furthermore, impaired mitochondrial respiration has been 
reported 2–72 hours after a single high dose of doxorubicin (20 mg/kg) in rats37. According to the present and 
these previous studies, the dosage of doxorubicin used and the time-points investigated may play important roles 
in doxorubicin-induced alterations in skeletal muscle mitochondrial function.
As a novel finding of the present study, doxorubicin treatment did not alter muscle capillary density and thus, 
decreased capillarization cannot explain the impaired running capacity. Also limb muscle independent factors 
can lie behind the persistently impaired running performance. Systemic doxorubicin administration has previ-
ously been shown to cause weakness and contractile dysfunction in diaphragm11,12, the principal respiratory mus-
cle. Doxorubicin-induced cardiotoxicity can also have an effect on whole body exercise capacity. Interestingly, 
sACVR2B-Fc could not prevent doxorubicin-induced cardiac atrophy (data not shown). This was, however, 
achieved by vascular endothelial growth factor-B (VEGF-B54) gene therapy in the same experimental setting 
(Räsänen et al. unpublished observations). The present study also showed that doxorubicin administration can 
reduce blood oxygen carrying capacity consistent with earlier reports55. However, this did not persist anymore 
two weeks after the cessation of doxorubicin administration. Thus, this effect probably does not play a major role 
in the persistently impaired running performance. It is likely that multiple factors, rather than just one, contribute 
to impaired exercise capacity by doxorubicin.
Contrary to previous results in wild type and dystrophic mice18,23, systemic sACVR2B-Fc administration did 
not cause any further impairment in running performance or mitochondrial content or function. Some more 
specific effects were, however, noticed. Unlike in wildtype or mice with muscular dystrophy18,23, citrate syn-
thase activity and the content of a mitochondrial channel protein porin/VDAC136 were increased in doxoru-
bicin treated mice administered with sACVR2B-Fc compared with doxorubicin alone. However, sACVR2B-Fc 
administration decreased mitochondrial respiratory chain subunit proteins CI-NDUFB8 and CV-ATP5A. This 
suggests that blocking ACVR2B ligands may have specific effects on mitochondrial proteins even though overall 
mitochondrial capacity or function may be unaltered. Previously, sACVR2B-Fc administration has decreased 
electron transport chain and oxidative phosphorylation gene sets in mdx mice22. As no effects on mitochondrial 
function or further decrease in running capacity were detected, these specific effects of blocking ACVR2B ligands 
have probably only minor physiological significance. Our laboratory has previously published evidence of inter-
action effects of exercise and sACVR2B-Fc in muscles18,22. Future studies should investigate the effects of blocking 
activin receptor ligands also in active mice.
Musculoskeletal system plays an important role in e.g. enabling locomotion. Bone can serve as an ion reserve 
to maintain serum ion concentrations of e.g. calcium and magnesium. Mechanical and molecular interaction 
between muscles and bone has got lots of attention during the last few years56. Many studies have shown that 
improving muscle size and strength can improve bone quantity or quality57. For instance, blocking myostatin/
activins has improved bone mass, quality and strength58. On the other hand, bone parameters have been reported 
to be decreased in rodents after doxorubicin administration59. The present study showed that the decrease in 
BMD and BMC by doxorubicin was prevented by sACVR2B-Fc and that the bone results are strongly related to 
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muscle mass. Therefore, it is speculated that changes in bone adaptation were secondary to muscle showing the 
importance of muscle per se on certain markers of health. However, the possible existence of other direct or indi-
rect effects of sACVR2B-Fc on bone cannot be excluded58.
In conclusion, unlike in many other cachexia-inducing diseases, our findings show that doxorubicin chemo-
therapy induces skeletal muscle atrophy without markedly increasing typical atrogenes or protein degradation 
pathways. In contrast, muscle atrophy induced by doxorubicin is probably mainly mediated by decreased protein 
synthesis, and this effect is prevented by blocking ACVR2B signalling. In addition, the current results suggest 
that blocking ACVR2B signalling may be a promising strategy to counteract chemotherapy-induced muscle and 
bone loss without further damage to skeletal muscle oxidative capacity or mitochondria or the actual treatment 
of malignancies.
Methods
Animals. C57BL/6J male mice (Envigo), aged 9–10 weeks, were used in all experiments. Mice were main-
tained under standard conditions (temperature 22 °C, 12:12 h light/dark cycle) with free access to food and water. 
The protocols were approved by the National Animal Experiment Board, and all the experiments were carried out 
in accordance with the guidelines of that committee.
Experimental design. Five experiments were conducted: 1–2) two four-week experiments, 3) a two-week 
experiment, 4) an acute experiment, and 5) a tumour experiment. In experiments 1–4, the mice were ran-
domly assigned into one of three groups: 1) vehicle (PBS) treated controls (Ctrl), 2) doxorubicin hydrochlo-
ride treated mice (Dox), and 3) doxorubicin treated mice administered intraperitoneally with sACVR2B-Fc 
(Dox + sACVR2B). In the tumour experiment (exp 5), the mice were randomized into five groups: 1) healthy 
controls (Ctrl), 2) LLC-tumour bearing mice (LLC + PBS), 3) LLC- mice treated with doxorubicin (LLC + Dox), 
4) LLC-mice treated with sACVR2B-Fc (LLC + sACVR2B), and 5) LLC-mice treated with doxorubicin and 
sACVR2B-Fc (LLC + Dox + sACVR2B).
Experimental treatments. In experiments 1–3, all doxorubicin administered mice received a total of four 
intraperitoneal injections of doxorubicin (6 mg/kg in PBS), administered every third day during the first two 
weeks of the experiment. Control mice were administered with an equal volume of PBS. In the four-week exper-
iments (1 and 2), the mice were euthanized four weeks after the first and 19 days after the last doxorubicin injec-
tion. In the two-week experiment (3), the mice were euthanized two weeks after the first and 4 days after the last 
doxorubicin injection. In these experiments, sACVR2B-Fc (5 mg/kg in PBS) was administered intraperitoneally 
for half of the doxorubicin treated mice twice a week during the first two weeks of the experiment and once a 
week after that (in the 4-week experiments). sACVR2B-Fc administration was started before the first doxorubicin 
injection and the last dose was administered seven days before euthanasia.
In the acute experiment, doxorubicin treated mice received a single intraperitoneal injection of doxorubicin 
(15 mg/kg in PBS) and controls an equal volume of PBS. sACVR2B-Fc treated mice received a single intraperito-
neal injection of sACVR2B-Fc (10 mg/kg in PBS) 48 hours before doxorubicin administration, a time-point when 
sACVR2B-Fc shows increased muscle protein synthesis19. The mice were euthanized 20 hours after doxorubicin/
PBS administration.
In the tumour experiment, mice were subcutaneously inoculated with 0.5 × 106 LLC cells (a kind gift from 
Dr. Alitalo) in 100 μ l of PBS or with an equal volume of vehicle only (controls) into the right abdominal region. 
Doxorubicin was administered intraperitoneally twice during the experiment on the sixth and eleventh day after 
tumour inoculation (cumulative dose 12 mg/kg). sACVR2B-Fc (5 mg/kg in PBS) was administered intraperito-
neally twice a week starting from third day after tumour inoculation and the last injection being two days before 
euthanasia. The mice were euthanized 14 days after tumour inoculation.
Tissue collection. At the end of all experiments, the mice were anaesthetized and then euthanized by heart 
puncture followed by cervical dislocation. Hindlimb muscles TA, gastrocnemius and soleus as well as epididymal 
fat pads were immediately excised and weighed. The left TA was snap-frozen in liquid nitrogen and the right TA 
muscle was mounted in O.C.T. embedding medium (Tissue Tek) and snap-frozen in isopentane cooled with liq-
uid nitrogen. All tissue weights were normalized to the length of the tibia (mm).
sACVR2B-Fc production. The recombinant fusion protein was produced and purified in house as described 
earlier in detail19. Briefly, the ectodomain of human ACVR2B was fused with a human IgG1 Fc domain and the 
fusion protein was expressed in Chinese hamster ovary cells grown in a suspension culture. The protein is similar, 
but not identical to that originally generated by Lee and colleagues17.
Tumour cell line and cell culture. LLC cells were originally purchased from American Type Culture 
Collection (Manassas, VA) and maintained in complete Dulbecco’s Modified Eagle’s Medium (DMEM) supple-
mented with 2 mmol/L L-glutamine, penicillin (100 U/mL), streptomycin (100 μ g/mL), and 10% FBS.
Dual-energy X-ray absorptiometry (DXA). For the DXA analysis, mice were anaesthetized with a com-
bination of ketamine and xylazine and imaged with Lunar PIXImus II densitometer (GE Healthcare). The images 
were analysed using standard procedures.
Treadmill running protocol. The mice ran first at 9, 12 and 15 m/min for 5 minutes each, after which the 
velocity was increased by 2 m/min every 2 minutes until exhaustion. All mice were familiarized with treadmill 
running on a separate day prior to the test.
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Muscle protein synthesis: in vivo surface sensing of translation. Muscle protein synthesis was ana-
lysed using surface sensing of translation (SUnSET) method32,33 as earlier in our laboratory19. At exactly 25 min 
after puromycin (Calbiochem) administration, mice were euthanized by heart puncture followed by cervical 
dislocation. Left TA muscle was isolated, weighed and snap-frozen in liquid nitrogen exactly 30 minutes after 
puromycin administration.
Mitochondrial function analysis. Skeletal muscle mitochondrial function was analysed with OROBOROS 
Oxygraph-2k high-resolution respirometer with similar procedures as earlier54. Briefly, a thin cross-section of 
5–10 mg from the middle of the left TA muscle was removed and temporarily stored in Biops buffer. The sample 
was then homogenized with a shredder and carbohydrate SUIT protocol was used to analyse mitochondrial 
function as previously described54.
RNA analysis. Total RNA was extracted from the TA muscle with TRIsure reagent (Bioline) and further 
purified with NucleoSpin® RNA II columns. For qPCR RNA was reverse transcribed to cDNA using iScriptTM 
Advanced cDNA Synthesis Kit for RT-qPCR (Bio-Rad Laboratories) according to the manufacturer’s instruc-
tions. Real-time qPCR was performed according to standard procedures using iQ SYBR Supermix (Bio-Rad 
Laboratories) and CFX96 Real-Time PCR Detection System (Bio-Rad Laboratories). Data analysis was carried 
out by using efficiency corrected Δ Δ Ct method. More information on qPCR is given in Supplementary methods.
RNA samples of five mice from each group were analysed with Illumina Sentrix MouseRef-6 v2 Expression 
BeadChip containing 45281 transcripts (Illumina Inc.) by the Functional Genomics Unit at Biomedicum 
Helsinki, University of Helsinki, Finland. Before the analysis, sample RNA was analysed for integrity and quality 
with Agilent Bioanalyzer 2100. Raw data were normalized with quantile normalization and data quality was 
assessed using Chipster software (IT Center for Science, Espoo, Finland)60. The complete data set is publicly 
available in the NCBI Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/; accession no. GSE77745). 
More detailed description is provided in Supplementary methods.
Protein extraction and content. TA muscle samples were homogenized in ice-cold buffer with proper 
inhibitors and further treated as earlier19,35 with slight modifications. Total protein content was determined 
using the bicinchoninic acid (BCA) protein assay (Pierce, Thermo Scientific) with an automated KoneLab device 
(Thermo Scientific).
Citrate synthase activity. Citrate synthase activity was measured from TA muscle homogenates using a kit 
(Sigma-Aldrich) with an automated KoneLab device (Thermo Scientific).
Western blotting. Western immunoblot analyses were performed as previously reported19,35, with slight 
modifications in the quantification of ubiquitinated proteins and puromycin incorporation: In the case of the 
analysis of puromycin-incorporated proteins and ubiquitinated proteins, the intensity of the whole lane was 
quantified. Ponceau S staining and GAPDH were used as loading controls and all the protein level results were 
normalized to the mean of Ponceau S and GAPDH, except for the puromycin-incorporated proteins that were 
normalized only to Ponceau S. The antibodies used are listed in the supplementary methods online.
Muscle immunohistochemistry. Cross-sections (10 μ m) were cut from TA muscle with a cryomicrotome. 
To analyse muscle fibre cross-sectional area (CSA), the sarcolemmas were visualized using antibodies against 
Dystrophin (Abcam) with Alexa Fluor 555 secondary antibody (Molecular Probes). This was combined with 
PECAM-1/CD31 (BD Pharmingen) staining with Alexa Fluor 488 secondary antibody (Molecular Probes) to 
visualize capillaries and DAPI for the nuclei. The stained sections were imaged with a confocal microscope (Zeiss) 
and ZEN software. The mean fibre CSA was quantified from 1,065 ± 58 fibres representing both the deep and 
the superficial regions of the muscle. For the analysis of fibre size distribution, 550 fibres were randomly picked 
from each muscle sample. Muscle fibre CSA, capillary density (capillaries/mm2) and capillary-to-fibre ratios were 
analysed with ImageJ software (NIH).
Statistical analyses. Values are presented as means ± SEM. The data from experiments 1 and 2 was pooled 
when there were no differences between the experiments. Data was checked for normality and differences 
between groups were analysed with general linear model ANOVA with Bonferroni post-hoc test, when appro-
priate. Western blot results were analysed with general linear model ANOVA with Bonferroni post-hoc test or 
with non-parametric Kruskal-Wallis test with Holm-Bonferroni corrected Mann-Whitney U as post-hoc when 
appropriate. Correlations were analysed using Pearson’s Product Moment Coefficient. Differences were consid-
ered statistically significant at P ≤ 0.05. Statistical analyses were performed with IBM SPSS Statistics version 22 
for Windows (SPSS, Chicago, IL).
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